Q-omics provides the consensus-scored FAM239A profile across patient tissues and cancer cell-line models. FAM239A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM239A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FAM239A RNA expression shows 8,798 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where FAM239A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM239A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM239A survival associations across molecular data types. FAM239A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM239A RNA expression–survival associations across cancer types. High FAM239A expression shows unfavorable associations in ACC, THCA, LUAD, LIHC and SKCM, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM239A RNA expression.
This table summarizes FAM239A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM239A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM239A shows lower tumor expression in KICH and higher tumor expression in KIRC, LUSC, CHOL, LUAD and COAD. The KIRC box plot shows higher FAM239A RNA expression in tumor versus normal tissue (log2 FC = +0.624, t-test p < 0.001).
This table shows molecular features associated with FAM239A in patient tissues and cancer cell lines. In patient samples, FAM239A shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM239A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
